{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "60b5e882c8324902a3ddfcd878426c34",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/US FDA Issues CRL for ZircaixUS FDA Issues CRL for Zircaix_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:22:55.405995",
      "extracted_at": "2025-10-26T12:22:55.406003"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 15,
        "successful_pages": 15,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.11379567655571632
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "a6988e073444723b",
      "text": "Australia | Biotechnology Telix",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8270827fd93e6d70",
      "text": "The US FDA has issued a CRL for Zircax. The FDA stated additional comparability data is required. In our view, this addressable delay implies at least a year's delay to reimbursement approval in the US. Hence, we now assume US reimbursement approval for this product at start FY27E (from start FY26E). Our risk- weighted valuation for this product declines to US \\(\\) 2.55\\(from US\\) \\ \\(3.68\\)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8eb0ae5a47b4e538",
      "text": "US FDA issues a CRL for Zircax - in our view at least a year's delay to reimbursement approval in the US. TLX announced that it has received a Complete Response Letter (CRL) from the United States Food and Drug Administration for the Biologics License Application for TLX250- CDx (Zircax). Telix believes these concerns are readily addressable and submission remediation will begin immediately. The Company will request a Type A meeting with the FDA soon.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b6e06b33982c7f12",
      "text": "In our view, the most important issue the FDA has relates to the nature of required comparability data. The CRL identifies issues relating to: 1) a requirement for additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled- up manufacturing process intended for commercial use. TLX management stated that this data has been collected by TLX and will be forwarded to the US FDA for review, as required. That said, the company does not know whether this data will be seen as adequate by the FDA; 2) The Chemistry, Manufacturing, and Controls package; and 3) Notices of deficiency (Form 483) issued to two third- party manufacturing and supply chain partners that will require remediation.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2cf91d11aff7677c",
      "text": "Should it ultimately be approved, TLX- 250CDx has the potential to become the standard in ccRCC diagnosis. Our discussions with KOLs suggest the current standard for diagnosis of ccRCC is CT scan, which has a \\(TARGET | ESTIMATE CHANGERATINGBUYPRICEAUD15.27*PRICE TARGET | % TO PT+ AUD26.70 (AUD29.30) | +75%52W HIGH-LOWAUD31.97 - AUD13.94FLOAT (%) | ADV MM (USD)76.3% | 44.81MARKET CAPAUD5.38 | $3.58TICKERTLX AU*Prior trading day&#x27;s closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a547b02a2f3c42d8",
      "text": "2025 ($)1HalfA2HalfFYEPS(0.00)0.020.02",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "168c31c925ba0b1a",
      "text": "Figure 1 - Telix - Illucxix sales revenue by quarter (US and EU) (A\\\\(m)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "92b01c1442159fda",
      "text": "Source: Company data, Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "44db005988097e0e",
      "text": "Figure 2 - Telix - Illucxix sales revenue by half (US and EU) (A\\\\(m)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4f95cb7ce3143144",
      "text": "Source: Company data, Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a006bec1d94f2c7b",
      "text": "Figure 3 - Telix - risk-weighted valuation by product",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "654b13af3adce002",
      "text": "Source: Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5084c4fee830a077",
      "text": "FY (Dec)2024A2025E2026E2027ERev. (MM)516.6798.9915.01,157.9Net Profit40.67.52.727.3EPS0.120.020.010.07FY P/E85.3xNMNMNM",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "68714619aa8a5cb2",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 9 - 15 of this report. \\\\* Jefferies (Australia) Pty Ltd",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a57a380bad460643",
      "text": "Investment in TLX is not without risks, but there is the potential for meaningful upside should its products be approved. TLX's major potential stumbling blocks are further positive late- stage clinical trial results and, then, regulatory approval. That said, if successful, TLX would likely gain significant market share in this relatively new field of medicine.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9ac634f7bca0359a",
      "text": "Base Case, AUD26.7, +75%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7621645616ba7508",
      "text": "Our price target uses our risk- weighted valuations for the TLX pipeline: 1) Diagnosis of Prostate Cancer; 2) Treatment of Prostate Cancer; 3) Diagnosis of Renal Cancer; 4) Treatment of Renal Cancer; 5) Diagnosis of Glioma; 6) Treatment of systemic amyloid light- chain amyloidosis. We also include an NPV of TLX's future royalty revenue.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "99ea48577cac9074",
      "text": "Upside Scenario, AUD34.53, +126%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e3b2017f199f2d1e",
      "text": "Our upside case is a non- risk- weighted valuation for our valuation of TLX's base- case opportunities.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3ff60650e0f8dab2",
      "text": "Downside Scenario, AUD9.83, - 36%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1b802d55ddbb8ba1",
      "text": "Our downside case assumes products on market continue to generate sales, i.e., all other clinical trials/registrational efforts fail.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dee265a09a2467c8",
      "text": "Pricing is a major issue. Device and drug pricing has always been tied to several social considerations of ESG, such as customer relationships, demographic changes, and social awareness, and it has continually been among the main measures of reputation and regulatory risk.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ac94000c64de1421",
      "text": "1) No targets for reducing the greenhouse gas emissions. \n2) Sustainability is a focus area for the business. Executive KMPs have specific sustainability measures included in the compensation framework. \n3) FY25 objective: TLX targets a majority of independent directors on the board. \n4) FY25 objective: Board composition target: Not less than \\(30\\%\\) female representation on the board. \n1HFY25 objective: Targeting to grow female representation in executive team.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d11b3c1d7bb603a6",
      "text": "1) How is TLX expanding its ESG framework in line with its R&D pipeline? \n2) How is TLX ensuring safe disposal of Radiopharmaceuticals? \n3) How is TLX ensuring safety of clinical trial participants?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "89a0d92acc109546",
      "text": "ESG Sector Deep Dive Update: Australian Healthcare",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "76eda9cab836f7d9",
      "text": "In terms of upside risks, TLX's product candidates use its technologies in the treatment/ diagnosis of 1) Prostate Cancer; 2) Kidney Cancer; 3) Glioma; and 4) Systemic amyloid light- chain amyloidosis. Success in any of these clinical trials would lead to a positive re- rating of TLX's share price, in our view.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6dd4f526532ba239",
      "text": "Figure 4 - Telix - expanded summary table (USSm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "19d5bed6d082c37e",
      "text": "Year-end 31 Dec (USSm)FY25AFY24AFY25EFY26EFY27ERevenue5177999151,158EBITDA4068585590EBIT3662393768Normalised NPAT29418327JEF NPAT/consensus (%)nananananaFully diluted norm EPS0.090.120.020.010.07EPS growth on pcp (%)na32.5nana909.7EV/EBITDA (x) (JEF)121.973.891.997.860.9EV/EBIT (x) (JEF)135.181.0135.8146.780.5FD normalised P/E (x) (JEF)169.2126.0688.91,911.6189.3Dividend yield (%)0.00.00.00.00.00ROE28.511.52.00.77.4Net debt/equity (%)net cashnet cash45.668.977.6",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1670556d2d14c027",
      "text": "Source: Company data, Jefferies estimates, Factset",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c0e9ac4333b83753",
      "text": "The US FDA has issued a CRL for Zircaloy. The FDA stated additional comparability data is required. In our view, this addressable delay implies at least a year's delay to reimbursement approval in the US. Hence, we now assume US reimbursement approval for this product at start FY27E (from start FY26E).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b61f01a99f48a926",
      "text": "Major changes to our forecasts include: 1) Delay to US reimbursement approval (and the start of significant revenues) for Zircaloy to start FY27E (from start FY26E); 2) Lower R&D spend in FY26E - in line with management comments, we now assume FY26E R&D spend increases in line with revenue growth (c15% from 25%); 3) Commensurate lower Manufacturing & Distribution and Sales & Marketing expenses in FY26E, as in our view, Zircaloy will not be sold in large volumes until FY27E; and 4) Net interest expense - this has been recalculated in line with period- end balances.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "741f6e02bff10e40",
      "text": "Figure 5 - Telix - changes to forecasts",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "9e66155bc74725d7",
      "text": "FY25EFY26EFY27EPrevRevDiff (%)PrevRevDiff (%)PrevRevDiff (%)Sales revenue (US$m)798.9798.90.01,055.0905.0(14.2)1,204.81,157.9(3.9)EBITDA (US$m)58.158.10.073.855.4(24.9)84.289.66.4EBIT (US$m)39.339.30.052.337.0(29.3)61.567.810.2NPAT (US$m)7.57.50.013.52.7(80.0)23.027.318.6EPS (US$ cps)2.12.10.03.70.7(80.0)6.27.418.6DPS (US$ cps)0.00.00.00.00.000.00.0Net op cashflow (US$m)22.422.40.031.518.9(39.8)43.147.09.0",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "700e9abade226ebf",
      "text": "Source: Company data, Jefferies estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "280b2772410f4ec4",
      "text": "TLX announced that it has received a Complete Response Letter (CRL) from the United States Food and Drug Administration for the Biologics License Application for TLX250- CDx (Zircaloy). Telix believes these concerns are readily addressable and submission remediation will begin immediately. The Company will request a Type A meeting with the FDA soon.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "62569c2d870b7eeb",
      "text": "The CRL identifies issues relating to: 1) a requirement for additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled- up manufacturing process intended for commercial use. TLX management stated that this data has been collected by TLX and will be forwarded to the US FDA for review, as required. That said, the company does not know whether this data will be seen as adequate by the FDA; 2) The Chemistry, Manufacturing, and Controls package; and 3) Notices of deficiency (Form 483) issued to two third- party manufacturing and supply chain partners that will require remediation.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2f4cdc7694837fcd",
      "text": "The US FDA identified a filing issue in the Chemistry, Manufacturing and Controls package with the specific filing concern relating to demonstrating adequate sterility assurance during dispensing of TLX250- CDx in the radiopharmacy production environment. The FDA indicated this issue required remediation for the application to advance to full review. The FDA did not indicate any deficiencies in the clinical or nonclinical data relating to the safety or efficacy of TLX250- CDx.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e71d29c6bb2b03fc",
      "text": "Our discussions with KOLs suggest that the current standard for diagnosis of ccRCC is CT scan, which has a \\(c70\\%\\) sensitivity. That said, when looking at smaller ccRCC lesions, KOLs believe CT scan sensitivity in the diagnosis of ccRCC is closer to \\(50\\%\\) . Hence, successful outcome for the trial, showing \\(85 + \\%\\) sensitivity and specificity, should mean that the TLX250- CDx should be used as the standard of care in Kidney Ca Diagnosis in time.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f07467d1371663ab",
      "text": "In addition, our previous research suggests there are a small number of organisations undertaking molecular targeted radiation clinical trials in the diagnosis of Renal Cancer - Telix is hence less likely to see competition over the medium- term in this indication.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fece20d829599a2a",
      "text": "Kidney cancer is the ninth most commonly occurring cancer in men and the 14th most commonly occurring cancer in women. There were over 430,000 new cases globally in 2022. Most kidney cancers are diagnosed as incidental findings on US, CT or MRI performed for another reason. \\(90\\%\\) of kidney cancers are renal cell carcinomas, with Transitional cell carcinoma (TCC) and Wilms tumour (nephroblastoma) making up the balance. \\(80\\%\\) of RCC is clear cell renal cell carcinoma, with papillary RCC (10%), chromophobe RCC (5%), and other types of RCC (5%) making up the balance.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a608b42b7e74e811",
      "text": "TLX250- CDx is an antibody- based imaging agent for use with Positron Emission Tomography (PET). TLX250- CDx targets a cell surface antigen called Carbonic Anhydrase IX (CAIX) which is expressed on the vast majority of clear cell renal cell cancers. CAIX antigen is present on \\(90 + \\%\\) of ccRCC cells but is absent from normal kidney tissues. ccRCC is the most common form of renal (kidney) cancer. CAIX is also highly expressed in many other cancers with poor prognosis, such as pancreatic, bladder, colorectal and lung cancers.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2075db90e7fbd102",
      "text": "Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron- emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3- D computed tomography images of the tracer concentrations within the body.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4a6dfc1668a3b2e1",
      "text": "TLX has previously stated that Renal imaging Total Addressable Market (TAM) was US\\\\$500m to US\\\\$750m. In time, TLX250- CDx may have potential utility in other cancers including metastatic ovarian cancer, metastatic urothelial cancer (transition cell), and infiltrating bladder cancer.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "63c3c48cfb21bce5",
      "text": "We have performed a scenario analysis for TLX's TLX250- CDx opportunity. There are a number of variables in this analysis. These include:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f8bfde377041b230",
      "text": "- Timeline for getting to market: We assume that TLX250-CDx gets major US reimbursement approval from public and private insurers at start FY27E in the US, and gets reimbursement approval at start of FY29E in the EU.- Size of the potential market: In FY26E, we assume Telix sells c33,300 doses - this implies c30% penetration of the market, assuming one scan per patient - below industry penetration in the first full year of PSMA-PET for Prostate Cancer.- Uptake of the product: We assume that volume of sales increases by 20% per annum for the first 3 years after the product enters the market. In years 4 to 6 after market entry, we assume volume of sales increase by 10% per annum, and in years 7 to 10 post market entry, we assume volume of sales increase 5% per annum.- Reimbursement: We assume an initial price in the US and EU for TLX of US\\(4.5K per dose. We assume price increases 1% per annum after market entry in the US and EU for the first 3 years in the market.- Exchange rate: Our FY25E A\\$/US\\$ exchange rate forecast is 0.65.- COGS per treatment: We assume initial COGS per treatment of US\\)1200 per dose.- Other COGS: We assume other COGS is 3% of TLX250-CDx sales.- Discount rate: In line with TLX's WACC, we use a WACC of c11% for this scenario analysis. We assume that the company's equity (and asset) beta is 1.80, in line with the average beta for higher-risk biotech opportunities.- Probability of success: According to data from Tufts University, USA (see below), the probability of success of clinical trials depends upon the stage of the clinical trial. We ascribe a 90% risk-weighting for the TLX250-CDx opportunity.- NPV per share: On the basis of the above, the risk-weighted NPV per share for the TLX250-CDx opportunity is US\\)2.55.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cb3d5ab06fdf8892",
      "text": "We enclose a summary of the number of patients who could benefit from TLX250- CDx in the US below.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b3d1b7a6168d3b2b",
      "text": "Figure 6 - Patients with a renal mass eligible for imaging with TLX250-CDx: US eligible patient population based on GLOBOCAN 2018",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f67f5f224b8c25a9",
      "text": "Notes: (1) GLOBOCAN 2018 reported incidence of kidney cancer in US. (2) Ljungberg B et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011 Oct;60(4):615-21. (3) JEF estimate.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9480cfa8811b35b8",
      "text": "Source: PubMed, Jefferies estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5ad7b5cbbc1f1d93",
      "text": "We enclose a summary of the number of patients who could benefit from TLX250- CDx in the EU below.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6db9927fbc07482b",
      "text": "Figure 7 - Patients with a renal mass eligible for imaging with TLX250-CDx: EU eligible patient population based on GLOBOCAN 2018",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1ad585e7055cc533",
      "text": "Notes: (1) GLOBOCAN 2018 reported incidence of prostate cancer in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Malta, Netherlands, Norway, Portugal, Spain, Sweden, UK. (2) Ljungberg B et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011 Oct;60(4):615-21. (3) JEF estimate.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "efe6d489df6a1851",
      "text": "As can be seen in the following figure, we note there are a smaller number of organisations undertaking MTR clinical trials in the diagnosis and treatment of Renal cancer - Telix is hence less likely to see competition over the medium- term in these indications.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a6120a31472f48b3",
      "text": "Figure 8 - TLX - Comps for TLX250CDx - Diagnostic PET agents for Renal Cancer",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e7ca35b0dc58851c",
      "text": "NameCompany developingDrug compositionLigand: Small molecule/mAb?IndicationMajor route of excretionRadiation sourceHalf life of RadiationClinical Stage/On marketMarket: US and/or EU?JEF commentCTT1057NovartisPhosphoramidate (18F)Small moleculeRenal cell carcinomaUrine, also biliary excretion.flourine-18109.7 mins*Phase 3naPhosphoramidate backbone irreversible bindingTLX250CDxTelix Pharmaceuticals892r-DFO-TFP-grientuximabmAbRenal cell carcinomaGastrointestinal tractzirconium-893.3 daysPhase 3EU and USZIRCON trial. TLX250CDx Antibody is licensed from Heidelberg Pharma AGAH111585GE HealthcareFluocitadineSmall moleculeRenal cell carcinomaKidneys/Urineflourine-18109.7 mins*Phase 2na892r-Df-CremilimabImaginAb, Inc.Small moleculeRenal cell carcinomaRenal cell carcinomaGastrointestinal tractzirconium-893.3 daysPhase 2na68Ga P16-093Five Eleven Pharma, IncPSMA-11 (Ga68)Small moleculeRenal cancer diagnosticKidneys/Urinegallium-6868 minsPhase 1na68Ga P16-093Five Eleven Pharma, IncPSMA-11 (Ga68)Small moleculeRenal cancer diagnosticGallium-68Phase 1F-18) VM4-037Siemens Molecular ImagingSmall moleculeRenal cell carcinomaRenal cell carcinomaKidneys/Urineflourine-18109.7 mins*Early Phase 1892r-bevacizumab PET scanNovartisSmall moleculeMetastatic Renal Cell Carcinoma",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9394b2c875409d19",
      "text": "Source: PubMed, Company data",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "66bd643067aadd42",
      "text": "Major changes to our forecasts include:",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6c632a51a37fb3a8",
      "text": "Delay to US reimbursement approval (and the start of significant revenues) for Zircaixto start FY27E (from start FY26E). Lower R&D spend in FY26E - in line with management comments, we now assume FY26E R&D spend increases in line with revenue growth ( \\(15\\%\\) from \\(25\\%\\) ). Commensurate lower Manufacturing & Distribution and Sales & Marketing expenses in FY26E - as in our view, Zircaix will not be sold in large volumes until FY27E. Net interest expense - this has been recalculated in line with period- end balances.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "404124d7e6a79b48",
      "text": "According to data from Tufts University, USA, the probability of success of clinical trials depends upon the stage of the clinical trial. This is seen in the following figure.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "78e2f662e59965ca",
      "text": "Figure 9 - Probability of drug at clinical phase stage ultimately getting to market (TuftsDiMasi data)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7986182348051aa2",
      "text": "PhaseProbability of success of moving to the next phase (%)Probability of drug getting onto market from a particular phase (%)Phase 162.513.4Phase 235.021.4Phase 368.061.2Filing90.090.0",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "bacc7b5084dfae3a",
      "text": "In terms of valuation, there are a number of potential commercial opportunities for TLX. These are: 1) Diagnosis of Prostate Cancer; 2) Treatment of Prostate Cancer; 3) Diagnosis of Renal Cancer; 4) Treatment of Renal Cancer; 5) Treatment of Glioblastoma Multiforme; 6) Treatment of systemic amyloid light- chain amyloidosis. We also include an NPV of TLX's future royalty revenue. This is seen in the following figure.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b29351c21fee4a63",
      "text": "Figure 10 - Telix - Valuation Methodology",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ad1c326213c5e082",
      "text": "Valuation of TLX R&D portfolioRisk-weighted valuation (US$ per share)Risk Weighting (in line with clinical trial stage)Total opportunity size (US$ per share)Ilucic/Gozellix - Prostate Cancer Dx9.83100.09.83TLX591 - Prostate Cancer Rx4.2961.27.01Zircaix (TLX250-CDx) - Kidney Cancer Dx2.5590.02.84TLX250 - Kidney Cancer Rx0.5521.42.55Pixcider (TLX101-CDx) - Glioma Dx0.2461.20.39Bensiloma0.07100.00.07Royalty revenue0.10Total valuation (US$)17.63AS/US exchange rate0.66Total valuation (AS, rounded)26.70",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4a942567fdd74ef5",
      "text": "Source: Jefferies estimates",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2bb712b0b9e2fcdd",
      "text": "Figure 11-Telix-Financial Summary (USSm)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3c1359d2e95dc0be",
      "text": "TelixPhamaceuticals Limited develops molecularly targeted radiation products for unmet needs in cancer care. Its lead products are llucic, used in the diagnosis of prostate cancer and now generating sales; TLX591, which is in clinical trials for the treatment of metastatic castrate- resistant prostate cancer; TLX250- CDx, which is awaiting US regulatory approval for the diagnosis of renal (kidney) cancer; TLX250, which is in clinical trials for the treatment of renal (kidney) cancer; TLX101- CDx, which is awaiting US regulatory approval for the diagnosis of Glioblastoma Multiforme (brain cancer); and Besilesomab, in clinical trials for the treatment of Systemic amyloid light- chain amyloidosis.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8c8d8b5c5de8c134",
      "text": "In terms of valuation, the major potential commercial opportunities for TLX are: 1) Prostate Cancer imaging and treatment; 2) Kidney Cancer imaging and treatment; 3) Glioblastoma Multiforme diagnosis; and 4) Systemic amyloid light- chain amyloidosis treatment. We use our risk- weighted valuations of the TLX pipeline to calculate our price target.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "7cd5cd47758978dc",
      "text": "Investment in TLX is not without risks, but we believe there is the potential for meaningful upside should its products be approved. TLX's major potential stumbling blocks are further positive late- stage clinical trial results and then, regulatory approval. That said, if successful, TLX would likely gain significant market share in this relatively new field of medicine. In terms of downside risks, there is still uncertainty around TLX's viability in most of its prospective markets. Pre- clinical trials, although positive, give no firm indication of a product's true viability, and future market conditions are unknown. To date, all pre- clinical and clinical trials have shown indications for the product's viability.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4ff07c3d178d5bcd",
      "text": "Our \\(95P\\) is based on 19x our 26 EPS estimate, which assumes multiple expansion from current levels looking 1 year fwd. Risks include regulatory delays, reimbursement challenges, competition, macro headwinds including staff shortages, supply chain challenges, inflation which could impact installation and procedure volumes, sales, EPS growth and margins.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "c86773a7c1d1879c",
      "text": "Valuation: Our Price Target is based on a 50:50 blend of P/E and NPV, assuming a \\(0\\%\\) premium to the sector 2026E PE and a \\(10\\%\\) discount to the NPV sum- of- the- parts valuation. Risks: Pricing/access, R&D, manufacturing, successful new launches, LOEs.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "33618f76efcb5543",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4b32a335ce83fe21",
      "text": "August 28, 2025 0:34 A.M. August 28, 2025 0:34 A.M.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "1da774a03ba9cde5",
      "text": "Jefferies LLC is acting as financial advisors to ImaginAb, Inc for Telix Pharmaceuticals Limited's acquisition of next- generation therapeutic assets and innovative biologics technology platform from ImaginAb, Inc. Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Telix Pharmaceuticals Ltd within the next three months. Within the past twelve months, Telix Pharmaceuticals Ltd has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4d29aeb52f2bc12c",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a1372ad5af355256",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a0ef19a30842d092",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6e3e6ba40c0ca007",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "86e894f646bbe9ab",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8fa6ec74ab322487",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5b8b53411841f8f9",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "15d99b9ade6d4f4f",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "14fd48bce170da2d",
      "text": "- GE HealthCare Technologies Inc (GEHC: \\(74.26, BUY) \n- Novartis AG (NOVN SW: CHF101.98, HOLD) \n- Novartis AG (NVS:\\)126.89, HOLD) \n- Telix Pharmaceuticals Ltd (TLX AU: AUD15.27, BUY)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a7f438bc0b3909ac",
      "text": "Rating and Price Target History for: Telix Pharmaceuticals Ltd (TLX AU) as of 08-27-2025",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "ecff8cfe348c72fd",
      "text": "Jefferies LLC is acting as financial advisors to ImaginaAb, Inc for Telix Pharmaceuticals Limited's acquisition of next- generation therapeutic assets and innovative biologics technology pl ImaginaAb, Inc.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "1e8a42d2be649673",
      "text": "Rating and Price Target History for: GE HealthCare Technologies Inc (GEHC) as of 08-27-2025",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "89dd38161e3d9c16",
      "text": "Rating and Price Target History for: Novartis AG (NVS) as of 08-27-2025",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "7fd4673f9fe507b7",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. Legend:",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "eaa2f078d23b3237",
      "text": "I: Initiating Coverage \nD: Dropped Coverage \nB: Buy \nH: Hold \nUP: Underperform",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8438ad726d184277",
      "text": "Distribution of RatingsIB Serv./Past12 Mos.JIL Mkt Serv./Past12 Mos.CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "36c117419325c726",
      "text": "Jefries does busines and seeks to do business with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c5649e760bc1b500",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "52240f745afedd06",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "f0d50cb3b607e3e9",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "7a75cc9764ff1088",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "a02b6a76b20b2b8d",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c2f945972e1d68a3",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3b56b8c474704c05",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "32f67e5dc352fe1d",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5b70733e31d1ba05",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6b30a94386613a37",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3f962e0411598039",
      "text": "first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "39f48e79132c82aa",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "b8b68ea52524afd0",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "3bccfd2b915c54d3",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "74c8afd175ef48e9",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e0686f27d457b120",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "72f1f7ad1977fe75",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "efb2facaa4281b8f",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0ba6fa2345e69586",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/lAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "18354035e2da9059",
      "text": "\\(①\\) 2025 Jefferies",
      "page": 14,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "146914ba3f2b493a",
      "name": "Australian Healthcare",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "99c55426eaf89a85",
      "name": "Biologics License",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ea73a91d24f4be50",
      "name": "Biotechnology Telix",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "89a4a18be3e0b42f",
      "name": "Carbonic Anhydrase",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "18e809158ceb265d",
      "name": "Catalysts\n\nIn",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e5de8e046c13857d",
      "name": "Cell Carcinoma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6f56a567abe0523f",
      "name": "Clinical Stage",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0c759b57d9ad2ce6",
      "name": "Company Specific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "599c003b7b8efa99",
      "name": "Complete Response",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d8af45e434b16fef",
      "name": "Deep Dive",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "529783a783014747",
      "name": "Diagnostic PET",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3525ddd519efdaa5",
      "name": "Differ\n\nInvestment",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1QFY22A",
              "2QFY22A",
              "3QFY22A",
              "4QFY22A",
              "1QFY23A",
              "2QFY23A",
              "3QFY23A",
              "4QFY23A",
              "1QFY24A",
              "2QFY24A",
              "3QFY24A",
              "4QFY24E"
            ]
          },
          "y": {
            "unit": "A$m",
            "range": {
              "min": 0,
              "max": 250
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "A$m",
            "values": [
              2,
              23,
              55,
              76,
              100,
              121,
              134,
              148,
              175,
              189,
              201,
              210
            ]
          }
        ],
        "figure_id": "7064756765ca1515",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1HFY22A",
              "2HFY22A",
              "1HFY23A",
              "2HFY23A",
              "1HFY24A",
              "2HFY24E"
            ]
          },
          "y": {
            "unit": "A$m",
            "range": {
              "min": 0,
              "max": 500
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "A$m",
            "values": [
              24,
              132,
              221,
              282,
              364,
              411
            ]
          }
        ],
        "figure_id": "1d21635a810e9aef",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [
          {
            "name": "TLX591 - Prostate Cancer Rx",
            "unit": "%",
            "values": [
              24
            ]
          },
          {
            "name": "Zircale (TLX250-CDB) - Kidney Cancer Dx",
            "unit": "%",
            "values": [
              15
            ]
          },
          {
            "name": "TLX250 - Kidney Cancer Rx",
            "unit": "%",
            "values": [
              3
            ]
          },
          {
            "name": "Paclara (TLX101-CDx) - Glioma Dx",
            "unit": "%",
            "values": [
              1
            ]
          },
          {
            "name": "Besilesomab",
            "unit": "%",
            "values": [
              0.4
            ]
          },
          {
            "name": "Royalty revenue",
            "unit": "%",
            "values": [
              1
            ]
          },
          {
            "name": "Illuccix/GozeRx - Prostate Cancer Dx",
            "unit": "%",
            "values": [
              55.6
            ]
          }
        ],
        "figure_id": "f084f3c84cfa5fe9",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 5,
              "max": 35
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "2024",
                "y": 10
              },
              {
                "x": "2025",
                "y": 25
              },
              {
                "x": "current",
                "y": 17.5
              }
            ]
          },
          {
            "name": "Upside Forecast",
            "unit": null,
            "values": [
              {
                "x": "current",
                "y": 17.5
              },
              {
                "x": "+12 mo.",
                "y": 34.53
              }
            ]
          },
          {
            "name": "Midpoint Forecast",
            "unit": null,
            "values": [
              {
                "x": "current",
                "y": 17.5
              },
              {
                "x": "+12 mo.",
                "y": 26.7
              }
            ]
          },
          {
            "name": "Downside Forecast",
            "unit": null,
            "values": [
              {
                "x": "current",
                "y": 17.5
              },
              {
                "x": "+12 mo.",
                "y": 9.83
              }
            ]
          }
        ],
        "figure_id": "395d32146a064c1c",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 6,
        "axes": {
          "x": null,
          "y": null
        },
        "series": [
          {
            "name": "Annual incidence of kidney cancer in US",
            "unit": "cases",
            "values": [
              {
                "value": 60000,
                "percentage": null,
                "label": "Annual incidence of kidney cancer in US"
              }
            ]
          },
          {
            "name": "Renal cell carcinoma",
            "unit": "cases",
            "values": [
              {
                "value": 54000,
                "percentage": 90,
                "label": "Renal cell carcinoma"
              }
            ]
          },
          {
            "name": "Eligible for imaging with TLX250-CDx",
            "unit": "cases",
            "values": [
              {
                "value": 54000,
                "percentage": 100,
                "label": "Eligible for imaging with TLX250-CDx"
              }
            ]
          }
        ],
        "figure_id": "1df2c6773cd4c2fc",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 6,
        "axes": {
          "x": null,
          "y": null
        },
        "series": [
          {
            "name": "Annual incidence of kidney cancer in EU-14",
            "unit": "people",
            "values": [
              {
                "value": 77000,
                "percentage": null
              }
            ]
          },
          {
            "name": "Renal cell carcinoma",
            "unit": "people",
            "values": [
              {
                "value": 69000,
                "percentage": 0.9
              }
            ]
          },
          {
            "name": "Eligible for imaging with TLX250-CDx",
            "unit": "people",
            "values": [
              {
                "value": 69000,
                "percentage": 1.0
              }
            ]
          }
        ],
        "figure_id": "1c11e3bf04a2074d",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 35
            }
          }
        },
        "series": [
          {
            "name": "BUY AUD",
            "unit": null,
            "values": [
              {
                "date": "2022-09-28",
                "value": 11.1
              },
              {
                "date": "2022-10-20",
                "value": 11.65
              },
              {
                "date": "2022-11-07",
                "value": 12.0
              },
              {
                "date": "2022-11-21",
                "value": 12.3
              },
              {
                "date": "2023-01-17",
                "value": 13.0
              },
              {
                "date": "2023-02-28",
                "value": 13.3
              },
              {
                "date": "2023-04-17",
                "value": 14.2
              },
              {
                "date": "2023-06-22",
                "value": 14.5
              },
              {
                "date": "2023-08-23",
                "value": 15.0
              },
              {
                "date": "2023-10-10",
                "value": 14.8
              },
              {
                "date": "2023-12-19",
                "value": 14.65
              },
              {
                "date": "2024-01-11",
                "value": 14.5
              },
              {
                "date": "2024-02-23",
                "value": 14.0
              },
              {
                "date": "2024-03-13",
                "value": 15.0
              },
              {
                "date": "2024-04-17",
                "value": 15.3
              },
              {
                "date": "2024-06-18",
                "value": 20.7
              },
              {
                "date": "2024-07-10",
                "value": 30.8
              },
              {
                "date": "2024-07-16",
                "value": 30.9
              },
              {
                "date": "2024-07-18",
                "value": 33.1
              },
              {
                "date": "2024-07-31",
                "value": 31.9
              },
              {
                "date": "2024-08-22",
                "value": 32.3
              },
              {
                "date": "2024-09-23",
                "value": 33.1
              },
              {
                "date": "2024-10-17",
                "value": 33.4
              },
              {
                "date": "2025-01-13",
                "value": null
              },
              {
                "date": "2025-02-04",
                "value": 33.7
              },
              {
                "date": "2025-02-21",
                "value": 33.0
              },
              {
                "date": "2025-04-22",
                "value": 35.3
              },
              {
                "date": "2025-04-28",
                "value": 34.5
              },
              {
                "date": "2025-07-22",
                "value": 34.0
              },
              {
                "date": "2025-08-05",
                "value": 32.7
              },
              {
                "date": "2025-08-22",
                "value": 29.3
              }
            ]
          }
        ],
        "figure_id": "2f30f97d0150dae1",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 55,
              "max": 95
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": null,
            "values": [
              57,
              70,
              85,
              70,
              75,
              95,
              80,
              85,
              95,
              90,
              60,
              75
            ]
          }
        ],
        "figure_id": "0ff7500c2ce5fb70",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": "Stock Price Trend with Buy/Hold Recommendations",
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "CHF",
            "range": {
              "min": 65,
              "max": 105
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "CHF",
            "values": [
              75,
              80,
              90,
              85,
              88,
              95,
              90,
              100,
              95,
              90,
              95,
              102
            ]
          }
        ],
        "figure_id": "6d7890e0e7d27212",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Novartis AG (NVS) as of 08-27-2025",
        "page": 12,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 60,
              "max": 130
            }
          }
        },
        "series": [
          {
            "name": "Stock Price",
            "unit": "$",
            "values": [
              {
                "date": "10/11/2022",
                "rating": "BUY",
                "target_price": 101.0
              },
              {
                "date": "12/12/2022",
                "rating": "BUY",
                "target_price": 107.0
              },
              {
                "date": "01/05/2023",
                "rating": "BUY",
                "target_price": 108.0
              },
              {
                "date": "04/18/2023",
                "rating": "BUY",
                "target_price": 112.0
              },
              {
                "date": "05/02/2023",
                "rating": "BUY",
                "target_price": 117.0
              },
              {
                "date": "07/24/2023",
                "rating": "BUY",
                "target_price": 121.0
              },
              {
                "date": "09/05/2023",
                "rating": "BUY",
                "target_price": 119.0
              },
              {
                "date": "10/11/2023",
                "rating": "BUY",
                "target_price": 110.0
              },
              {
                "date": "10/30/2023",
                "rating": "BUY",
                "target_price": 111.0
              },
              {
                "date": "01/03/2024",
                "rating": "BUY",
                "target_price": 119.0
              },
              {
                "date": "01/16/2024",
                "rating": "BUY",
                "target_price": 123.0
              },
              {
                "date": "02/05/2024",
                "rating": "BUY",
                "target_price": 122.0
              },
              {
                "date": "04/10/2024",
                "rating": "BUY",
                "target_price": 116.0
              },
              {
                "date": "04/26/2024",
                "rating": "BUY",
                "target_price": 120.0
              },
              {
                "date": "05/14/2024",
                "rating": "BUY",
                "target_price": 121.0
              },
              {
                "date": "07/02/2024",
                "rating": "BUY",
                "target_price": 122.5
              },
              {
                "date": "09/03/2024",
                "rating": "HOLD",
                "target_price": 123.5
              },
              {
                "date": "10/03/2024",
                "rating": "HOLD",
                "target_price": 124.0
              },
              {
                "date": "01/20/2025",
                "rating": "HOLD",
                "target_price": 110.0
              }
            ]
          }
        ],
        "figure_id": "98b0e54ca3f28fe9",
        "provenance": {
          "page": 12
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "902ce65c69944bed",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>PRICE</td><td>AUD15.27*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>+ AUD26.70 (AUD29.30) | +75%</td></tr><tr><td>52W HIGH-LOW</td><td>AUD31.97 - AUD13.94</td></tr><tr><td>FLOAT (%) | ADV MM (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2f2ec754eabafde2",
        "value": 0.763,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>52W HIGH-LOW</td><td>AUD31.97 - AUD13.94</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>76.3% | 44.81</td></tr><tr><td>MARKET CAP</td><td>AUD5.38 | $3.58</td></tr><tr><td>TICKER</td><td>TL",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a95a7aa5158465b3",
        "value": 26.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "nterest expense - this has been recalculated in line with period- end balances. Telix- valuation A\\$26.70 (from A\\$29.30). We have updated our forecasts and A\\$/US\\$ exchange rate, and hence our NPV- ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "26e3a3bbd69c95da",
        "value": 29.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "- this has been recalculated in line with period- end balances. Telix- valuation A\\$26.70 (from A\\$29.30). We have updated our forecasts and A\\$/US\\$ exchange rate, and hence our NPV- based valuation ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4d8d676b3e4c9485",
        "value": 26.7,
        "unit": "$",
        "metric_type": "currency",
        "context": "e updated our forecasts and A\\$/US\\$ exchange rate, and hence our NPV- based valuation for TLX is A\\$26.70. Our NPV- based valuation of the TLX late- stage pipeline is our price target. TARGET | ESTIM",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8f3b400f8b9e1f03",
        "value": 3.58,
        "unit": "$",
        "metric_type": "currency",
        "context": "tr><td>FLOAT (%) | ADV MM (USD)</td><td>76.3% | 44.81</td></tr><tr><td>MARKET CAP</td><td>AUD5.38 | $3.58</td></tr><tr><td>TICKER</td><td>TLX AU</td></tr><tr><td colspan=\"2\">*Prior trading day&#x27;s ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "09f02a51edb81a39",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "![Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> Base Case, AUD26.7, +75% Our price target uses our risk- weighted valuations for the TLX pipeline: 1) Diagnosis of Prostate",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "7e7832e7415d51b4",
        "value": 1.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "in amyloidosis. We also include an NPV of TLX's future royalty revenue. Upside Scenario, AUD34.53, +126% Our upside case is a non- risk- weighted valuation for our valuation of TLX's base- case opport",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "360f7f68f244c038",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ghted valuation for our valuation of TLX's base- case opportunities. Downside Scenario, AUD9.83, - 36% Our downside case assumes products on market continue to generate sales, i.e., all other clinical",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "59554d949c07572a",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ine with management comments, we now assume FY26E R&D spend increases in line with revenue growth (c15% from 25%); 3) Commensurate lower Manufacturing & Distribution and Sales & Marketing expenses in ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5ec9432af2ab317a",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "management comments, we now assume FY26E R&D spend increases in line with revenue growth (c15% from 25%); 3) Commensurate lower Manufacturing & Distribution and Sales & Marketing expenses in FY26E, as",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cef5b1795d02fa0f",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "oma) making up the balance. \\(80\\%\\) of RCC is clear cell renal cell carcinoma, with papillary RCC (10%), chromophobe RCC (5%), and other types of RCC (5%) making up the balance. ## TLX250-CDx (89Zr-g",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7dc1a70b263f688b",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nce. \\(80\\%\\) of RCC is clear cell renal cell carcinoma, with papillary RCC (10%), chromophobe RCC (5%), and other types of RCC (5%) making up the balance. ## TLX250-CDx (89Zr-girrentuximab) TLX250- C",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a9aca831d8c2144e",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "cell renal cell carcinoma, with papillary RCC (10%), chromophobe RCC (5%), and other types of RCC (5%) making up the balance. ## TLX250-CDx (89Zr-girrentuximab) TLX250- CDx is an antibody- based imag",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d5fd82825591a9da",
        "value": 500.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "one scan each TLX has previously stated that Renal imaging Total Addressable Market (TAM) was US\\\\$500m to US\\\\$750m. In time, TLX250- CDx may have potential utility in other cancers including metasta",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2071170df40309ba",
        "value": 750.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "h TLX has previously stated that Renal imaging Total Addressable Market (TAM) was US\\\\$500m to US\\\\$750m. In time, TLX250- CDx may have potential utility in other cancers including metastatic ovarian ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "94a9cfe9dfa64ca5",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "he EU.- Size of the potential market: In FY26E, we assume Telix sells c33,300 doses - this implies c30% penetration of the market, assuming one scan per patient - below industry penetration in the fir",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b20475694e982d3d",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f PSMA-PET for Prostate Cancer.- Uptake of the product: We assume that volume of sales increases by 20% per annum for the first 3 years after the product enters the market. In years 4 to 6 after marke",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e4b6d01a8aded33d",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "roduct enters the market. In years 4 to 6 after market entry, we assume volume of sales increase by 10% per annum, and in years 7 to 10 post market entry, we assume volume of sales increase 5% per ann",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ed65a9317216e322",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "crease by 10% per annum, and in years 7 to 10 post market entry, we assume volume of sales increase 5% per annum.- Reimbursement: We assume an initial price in the US and EU for TLX of US\\(4.5K per do",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "36b4debdc486354d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "We assume an initial price in the US and EU for TLX of US\\(4.5K per dose. We assume price increases 1% per annum after market entry in the US and EU for the first 3 years in the market.- Exchange rate",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "cabf8a17f595f2e0",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nt: We assume initial COGS per treatment of US\\)1200 per dose.- Other COGS: We assume other COGS is 3% of TLX250-CDx sales.- Discount rate: In line with TLX's WACC, we use a WACC of c11% for this scen",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1a6a2a763ca3017e",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "me other COGS is 3% of TLX250-CDx sales.- Discount rate: In line with TLX's WACC, we use a WACC of c11% for this scenario analysis. We assume that the company's equity (and asset) beta is 1.80, in lin",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "92f7d6f957f542aa",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "robability of success of clinical trials depends upon the stage of the clinical trial. We ascribe a 90% risk-weighting for the TLX250-CDx opportunity.- NPV per share: On the basis of the above, the ri",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bd710054f1825b29",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "19cddc8ed6f225d4",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "d7daaa53ab24fc9d",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "6a137bdd6288ea81",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "91d86855a7d8f1b3",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "3173741a92723c06",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "c7c5c1c4852f8f0f",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "17611ea6a815b99b",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "1b40fca233931134",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 10,
      "tables_count": 0,
      "numerical_data_count": 33,
      "passages_count": 112,
      "entities_count": 20
    }
  }
}